Celerion, a CRO to the biopharmaceutical industry, has completed additions to its research capacity and services, including a new Screening and Return Center, upgraded pharmacy compounding suites, expanded Absorption, Distribution, Metabolism and Excretion (ADME) lab capacity and fifty additional beds.
 

The new 40,000 sq.-ft. facility adjacent to the Phoenix, AZ clinic is designed to increase screening capacity and cater to the participant experience. It allows Celerion to better segregate ongoing in-house clinical trials and outpatient visits and screening to increase throughput and volume.  
 

The addition of fifty new beds increases the total bed capacity to 350 at their Phoenix, AZ Clinical Pharmacology Unit, and brings Celerion’s total global bed count to over 650 beds.  These additional units are designed for complex Phase I protocols including first-in-human, intense cardiac monitoring, thorough QT studies and unique biomarker collections and procedures. This also adds increased capacity to Celerion’s core clinical pharmacology studies such as drug-drug interaction, bioavailability and bioequivalence studies.
 

“The industry’s critical need for early phase clinical research continues to validate our aggressive expansion strategy,” says Phil Bach, Celerion’s Vice President of Global Clinical Research. “These latest facility upgrades provide a timely boost to our overall clinical capacity, capabilities, and start up timelines even beyond the unique needs generated by a global pandemic.” 

 

Bach adds that doubling the ADME Lab capacity in Lincoln, NE gives clients additional flexibility in scheduling human mass balance studies. Celerion has invested in new state-of-the-art equipment and laboratory space to expand on-site scintillation counting, allowing for radioactivity recovery results to be delivered in real time. The on-site laboratory and Phase I clinical facilities offer seamless integration of services and data, he says.